ArticleJournal of translational autoimmunity2026
Serum pepsinogen Ⅰ and the pepsinogen Ⅰ/Ⅱ ratio as a non-invasive predictive marker for autoimmune metaplastic atrophic gastritis.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Autoimmune metaplastic atrophic gastritis (AMAG) is a chronic inflammatory disease characterized by autoimmune destruction of parietal cells, causing profound gastric body and fundus atrophy. AMAG is frequently overlooked or misdiagnosed in clinical practice. This study aimed to identify optimal cut-off values for serum pepsinogens (PGs) as a non-invasive diagnostic tool for AMAG in a retrospective cohort. Methods: We retrospectively analyzed the clinical and laboratory data of 520 AMAG patients from our center and compared them with those of 223 control patients who underwent serum PG testing and esophagogastroduodenoscopy (EGD) for various indications during the same period. Results: The AMAG cohort demonstrated a marked female predominance compared with controls (74.6% vs. 45.2%, p < 0.001), and 23.1% of patients were asymptomatic at diagnosis. Serological profiling showed that anti-parietal cell antibody was positive in 65.9% (309/469) of tested individuals, while anti-intrinsic factor antibody was detected in 39.1% (61/156). Gastric neuroendocrine tumors (NETs) were the most frequent neoplastic finding in AMAG (105 patients, 20.2%). Fasting gastrin-17 levels were significantly elevated in AMAG patients alongside markedly decreased pepsinogen I (PG I) and PG I/II ratio compared with controls (all p < 0.001). Receiver operating characteristic analysis identified PG I < 22.45 ng/mL (AUC: 0.964, 95% CI: 0.950-0.978; sensitivity: 88.9%, specificity: 96.0%) and PG I/II ratio <2.25 (AUC: 0.957, 95% CI: 0.941-0.974; sensitivity: 89.6%, specificity: 95.1%) as optimal cut-offs for distinguishing AMAG from controls. The combined use of PG I < 22.45 ng/mL and PG I/II ratio <2.25 achieved a specificity of 97.3% (95% CI: 94.2%-99.0%). Conclusions: Serum PG I and the PG I/II ratio demonstrate good diagnostic performance for AMAG, with high specificity in particular. These biomarkers may serve as a useful non-invasive screening tool for AMAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.